One-Pot Multicomponent Synthesis of Novel 2-Tosyloxyphenylpyrans under Green and Conventional Condition with Anti-inflammatory Activity

Article abstract of DOI:10.1002/jhet.2730

A mild, efficient, and environmentally green protocol for the synthesis of 2-tosyloxyphenylpyran derivatives 3, 4, 5, 6, 7, 8, 9, 10, 11 via reaction of 2-tosyloxybenzaldehyde (1) with malononitrile and some ketonic reagents in one-pot, three component re

Full text of DOI:10.1002/jhet.2730

Month 2016
One-Pot Multicomponent Synthesis of Novel 2-Tosyloxyphenylpyrans
under Green and Conventional Condition with Anti-inflammatory Activity
a
a
b
a
*
Ahmed Khodairy, Ali M. Ali, Moustafa O. Aboelez, and M. T. El-Wassimy
aDepartment of Organic Chemistry, Faculty of Science, Sohag University, Sohag 82524, Egypt
bDepartment of Pharmaceutical Medicinal Chemistry, Faculty of Pharmacy, Sohag University, Egypt
*E-mail: elssan@yahoo.com
Additional Supporting Information may be found in the online version of this article.
Received April 16, 2016
DOI 10.1002/jhet.2730
Published online 00 Month 2016 in Wiley Online Library (wileyonlinelibrary.com).
A mild, efficient, and environmentally green protocol for the synthesis of 2-tosyloxyphenylpyran
derivatives 3-11 via reaction of 2-tosyloxybenzaldehyde (1) with malononitrile and some ketonic reagents
in one-pot, three component reaction within few minutes under stirring in methanol in presence of ammonium
hydroxide solution or ultrasonic irradiation. On the other hand, the same products 3-11 were obtained by
traditional method, on treatment of 2-tosyloxybenzilidinemalononitrile (2) with the same ketonic reagents
in refluxing ethanol in presence of TEA. 2-Tosyloxyphenylpyranopyrazoles 12 and 13 were obtained via
treatment of compound 1 with malononitrile, hydrazine hydrate or phenyl hydrazine and ethyl acetoacetate,
in one-pot, multicomponent reaction (MCRs). The structures of the new compounds were elucidated by ele-
mental and spectral analyses. The newly synthesized compounds showed promising anti-inflammatory activity.
J. Heterocyclic Chem., 00, 00 (2016).
INTRODUCTION
using green or conventional conditions and screen their anti-
inflammatory activity.
4H-Pyran derivatives comprise an important class of
heterocyclic compounds because of their interesting biologi-
cal and pharmacological activities [1], such as antimicrobial
[2], anti-inflammatory [3], anticancer [4], anti-HIV [5],
antidyslipidemic [6], antimalarial [7], antihyperglycemic,
and cytotoxic [8]. Multicomponent reactions (MCRs) are
defined as those reactions in which three or more compounds
react together in one pot to form a new product [9] and have
proved to be very influential and efficient bond-forming
tools in organic synthesis and medicinal chemistry [10]. In
recent years, the focus on green chemistry using environ-
mentally benign reagents and conditions is one of the most
fascinating developments in the synthesis of widely used
organic compounds [11]. The use of water as a promising
solvent for organic reactions has received considerable
attention in the area of organic synthesis owing to its green
credentials [11–14] and has been used for MCRs [15,16].
Over the last two decades, sonichemical methods have
become widely used in heterocyclic synthesis [17–19]
because they can be carried out in a higher yield, shorter
reaction time and milder conditions [20–24].
RESULTS AND DISCUSSION
2-Tosyloxybenzaldehyde (1) was simply prepared via
the reaction of salicylaldehyde with tosyl chloride under
reflux acetonitrile in the presence of sodium carbonate [9]
(Scheme 1).
Stirring of 2-tosyloxybenzaldehyde (1) with malononitrile
in the presence NH4OH solution afforded 2-tosyloxy-
benzylidinemalononitile (2) (Scheme 1). IR spectrum of
compound 2 showed an absorption band at 2215cmꢀ1
1
because of CN group. Its H NMR (δ DMSO-d6) spectrum
showed the disappearance of CHO group signal and appear-
ance of two singlet signals at δ 8.11 and 2.47 ppm attributed
to C¼H and CH3 groups, respectively.
2-Tosyloxyphenylpyran derivatives 3–6 were prepared
via MCR of 2-tosyloxybenzaldehyde (1) with malononitrile
and ketonic derivatives, namely acetylacetone, ethyl
acetoacetate, benzoylacetone, and ethyl benzoylacetate via
stirring in a mixture of ammonium hydroxide and methanol
or under ultrasonic wave irradiation in sodium chloride
solution (0.5M) (Scheme 2).
Therefore, in view of these observations and in conjunction
with our previous interest in synthesis heterocyclic rings
[11,25,26], we report herein the synthesis of novel 2-
tosyloxyphenylpyrans and 2-tosyloxyphenylpyranopyrazoles
Excellent yields were obtained in both methods (81–91%)
within short reaction times (2–5 min) and problems associated
© 2016 Wiley Periodicals, Inc.

A. Khodairy, A. M. Ali, M. O. Aboelez, and M. T. El-Wassimy
Vol 000
Scheme 1. Synthesis of 2-tosyloxybenzylidine malononitile.
the presence of TEA, the same products 3–6 were obtained
in moderate yields (67–79%) and longer reaction times
(3 – 5 h) (Scheme 2; Table 1).
IR spectra of compounds 3–6 revealed the appearance of
two new bands in the range 3391–3224 cmꢀ1 for NH2
groups, CN groups in the range 2202–2189cmꢀ1, and
carbonyl groups at 1661acetyl, 1701ester, and 1703ester
cmꢀ1, respectively. 1H NMR (δ-DMSO-d6) spectra
showed, in addition to the expected aromatic proton signals,
a singlet signal corresponding to NH2 groups in the region δ
7.05–6.77ppm which disappeared on deuteration and a
with toxic solvent used (cost, safety, and pollution) were
avoided (Table 1).
On treatment of 2-tosyloxybenzylidinemalononitile (2)
with the previous ketonic reagents under reflux ethanol in
Scheme 2. Synthesis of 2-tosyloxyphenylpyrans.
Table 1
Comparison of the reaction times and yields for synthesis 2-Tosyl-oxyphenylpyrans (green and traditional methods).
Conventional method/EtOH/TEA
Stirrer in MeOH/NH4OH
Ultra sonic wave/H2O/NaCl
Comp.
No.
Yield %
Time (h)
Yield %
Time (min)
Yield %
Time (min)
3
4
5
6
7
8
9
10
11
79
78
71
67
69
71
66
74
42
4
5
3
3
5
4
5
4
4
89
84
83
91
86
92
94
88
87
3
2
5
4
3
5
4
7
7
86
81
82
84
79
90
89
87
85
3
5
3
2
3
3
5
3
5
Journal of Heterocyclic Chemistry
DOI 10.1002/jhet

Month 2016
One-Pot Multicomponent
new singlet signal in the region δ 4.75–4.37ppm consistent
with the CH pyran. Furthermore, 1H NMR (δ DMSO-d6) of
compounds 4 and 5 showed quartet and triplet signals in
the region δ 3.97–3.80 and 0.99–0.76ppm for CH2 and
CH3 of the ester groups, respectively. 13C NMR spectrum
of compound 4 showed the appearance of new signals at δ
21.61, 18.58, and 14.02 ppm because of the three methyl
groups, a new signal at 165.67ppm because of the CO
group, and negative signal at δ 56.62ppm for CH2 group
in DEPT 135.
By the same ways, MCR between compound 1 with
malononitrile and some cyclic ketones namely;
cyclopentanone, cyclohexanone, 1,3-cyclohexanedione,
cycloheptanone, or dimidone under stirring in methanol
in the presence of ammonium hydroxide solution or ul-
trasonic irradiation technique within few minutes afford
2-tosyloxyphenylpyran derivatives 7–11, respectively
(Scheme 4).
Excellent yields were obtained in (85–92%) within short
reaction times (3–7min) (Table 1).
The formation of compound 4 can be explained by the
possible mechanism presented in Scheme 3. The reaction
can occur via initial formation of the α,β-unsaturated com-
pound 2 via Knoevenagel condensation reaction between
aldehyde 1 and malononitrile, which undergoes nucleo-
philic attack of ethyl acetoacetate anion to give the Michael
adduct. Then, the latter promotes, cyclization to compound
4 via nucleophilic attack of enolized OH group to CN
group. However, an alternative mechanism cannot be ruled
out, in which the pathway starts from the reaction between
1 and ethyl acetoacetate to generate the α,β-unsaturated
compound A, which in turn undergoes an addition of
malononitrile anion to afford adduct B. Then nucleophilic
attack of enolized OH group to CN group.
On the other hand, the same products 7–11 were ob-
tained on treatment of compound 2 with the previous
cyclic ketones under reflux in ethanol and TEA. Moderate
yields (66–74%) were obtained in longer reaction times
(3–5 h) (Table 1).
The IR spectra of compounds 7–11 showed two absorp-
tion bands at 3359–3215cmꢀ1 because of NH2 groups,
2206–2183cmꢀ1 for CN groups, and 1678 cmꢀ1 because
1
of CO group in compound 9. The H NMR (δ DMSO-
d6) spectra of compounds 7–11 showed, besides the
expected aromatic protons signals, new singlet signal in
the region δ 7.19 – 6.98 ppm consistent with the NH2
groups which disappeared on deuteriation, in addition to
a singlet signal corresponding to CH
in the region δ
pyran
Scheme 3. Proposed mechanisms for the synthesis of pyrans.
Journal of Heterocyclic Chemistry
DOI 10.1002/jhet

A. Khodairy, A. M. Ali, M. O. Aboelez, and M. T. El-Wassimy
Vol 000
Scheme 4. Synthesis of 2-tosyloxyphenylpyrans.
4.44–4.16 ppm. Furthermore, 13C NMR spectrum of com-
pound 9 showed C¼O group signal at δ 195.93 ppm.
It was shown that, the green method is considered as
environment-friendly and economically for synthesis of
2-tosyloxyphenylpyran derivatives.
NH2 groups in the region δ 6.81 ppm and 7.09 ppm, respec-
tively, which disappeared on deuteriation, in addition to
singlet signal at δ 4.92 and 4.85 ppm consistent with the
CH pyran, and new signals at δ 1.74 and 1.76ppm because
of the CH3
groups, respectively. Furthermore,
pyrazole
On treatment of 2-tosyloxybenzaldehyde (1) with
malononitrile, hydrazine hydrate or phenyl hydrazine, and
ethyl acetoacetate, in one-pot, four component process in
refluxing ethanol in the presence of TEA, 2-tosyloxyphe-
nylpyranopyrazoles 12 and 13, were yielded (Scheme 5).
IR spectra of compounds 12 and 13 revealed two
absorption bands in the range 3369–3219 cmꢀ1 because
of NH2 groups, in addition to CN groups at 2196 and
2203 cmꢀ1. 1H NMR (δ-DMSO-d6) spectra of compounds
12 and 13 showed, new singlet signals corresponding to
compound 12 showed, new singlet signal at δ 12.10ppm
because of NH group. 13C NMR spectrum of compound
12 showed a new signal at δ 9.98ppm because of the
CH3 pyrazole group and at δ 30.61 ppm for CH
group.
pyran
ANTI-INFLAMMATORY ACTIVITY
Anti-inflammatory activity screening for the selected
compounds 3, 4, 5, 6, 7, 9, 10, and 11 was determined in
Scheme 5. Synthesis of 2-tosyloxyphenylpyranopyrazoles.
Journal of Heterocyclic Chemistry
DOI 10.1002/jhet

Month 2016
One-Pot Multicomponent
vivo by the acute carrageenan-induced paw edema standard
method in rats Winter et al. [27]. Adult albino rats of either
sex (pregnant female animals were excluded) weighing
160–190g were divided into 11 groups of 8 animals, all
rats were fasted overnight, then on the next day (day of
experiment), animals were uniformly hydrated by giving
3 mL of water per rat orally. Indomethacin, celecoxib
(reference standards), and the tested compounds (100 mg/
kg body weight) were suspended in saline solution by the
aid of few drops of Tween 80 and given orally 1 h before
induction of inflammation. The control group was given
saline solution containing few drops of Tween 80.
Carrageenan paw edema was induced according to a
modified method of Winter et al. [27] by subcutaneous
injection of 1% solution of carrageenan in saline (0.1 mL/
rat) into the sub planter region of the right hind paw of rats.
The thickness of rat paw was measured by mercury digital
micrometer at different time intervals, at zero time and
after 1, 2, and 3 h of carrageenan injection. The edema
was determined from the difference between the thickness
of injected and non-injected paws. Data were collected,
revised, and analyzed. Quantitative variables from normal
distribution were expressed as means SE “standard er-
ror”. The significant difference between groups was tested
by using one-way ANOVA followed by post hoc test at
p <0.05 and p< 0.01 (Table 2). The results of the anti-
inflammatory activity were expressed as percentage inhibi-
tion of edema thickness in treated animals in comparison
with the control group according to the following equation:
group of rats, and (VR ꢀ VL)treated represents the mean in-
crease in paw thickness in rats treated with the tested com-
pounds [28–30].
From the obtained results, we observed that all the tested
compounds show considerable anti-inflammatory activity;
compounds 3, 4, 7, 10, and 11 exhibit excellent anti-
inflammatory properties.
EXPERIMENTAL
All melting points were recorded on Melt-Temp II melting
point apparatus. IR spectra were measured as KBr pellets on
a Shimadzu DR-8001 spectrometer. 1H NMR and 13C NMR
spectra were recorded on a Bruker at 400MHz and 100MHz
using TMS as an internal reference and DMSO-d6 as a
solvent. The elemental analyses were carried out on a
Perkin-Elmer 240C Micro analyzer. The ultrasonic irradia-
tion was performed by using a Branson ultrasonic cleaner
bath, model 1510, AC input 115V, output 50W, and 1.9L
with a mechanical timer (60min with continuous hold). All
compounds were checked for their purity on TLC plates.
Synthesis of 2-tosyloxybenzylidenemalononitrile (2).
A
mixture of 2-tosyloxybenzaldehyde (1) (0.002mol, 0.55g)
and malononitrile (0.002mol, 0.13g), in methanol (5mL),
containing drops of NH4OH was stirred for 2 min. The
formed solid product was filtered off, washed with small
amounts of water, dried, and crystallized from ethanol. m.
p. 152–153°C, IR (KBr) 2215 (C ≡N), 1378, 1146 (SO2)
1
cmꢀ1; H NMR (DMSO-d6): 8.11 (s, 1H¼CH), 7.91 (d,
ðVR-VLÞcontrol-ðVR-VLÞtreatedꢁ100
% of edema inhibition ¼
ðVR-VLÞcontrol
1H, J=4Hz, Ar―H), 7.80 (t, 1H, Ar―H), 7.69 (d, 2H,
J=8Hz, Ar―H), 7.60 (t, 1H, Ar―H), 7.51–7.45 (m, 3H,
Ar), 2.47 (s, 3H, CH3); 13CNMR: δ 156.12, 153.09, 138.45,
132.57, 130.65, 129.24, 128.11, 126.13, 121.01, 116.42,
114.23, 112.23, 83.14, 21.04,: Anal. Calcd. for
C17H12N2O3S (324.45): C (62.95%), H (3.73%), N
(8.64%), S (9.89%) Found: C (63.02%), H (3.67%), N
(8.59%), S (9.96%).
where VR represents the mean right paw thickness, VL rep-
resents the mean left paw thickness (VR ꢀVL)control repre-
sents the mean increase in paw thickness in the control
Table 2
Anti-inflammatory activity of tested compounds using carrageenan-induced
paw edema in rats.
General procedure for preparation of 2-tosyloxyphenylpyrans
3 – 11. Method A. A mixture of compound 1 (0.002mol,
0.55 g), malononitrile (0.002 mol, 0.13 mL), and appropriate
ketonic reagents (0.002 mol), namely acetylacetone
(0.21 mL), ethyl acetoacetate (0.26 mL), benzoylacetone
(0.30 gm), ethyl benzoylacetate (0.34mL), cyclopentanone
(0.18mL), cyclohexanone (0.21mL), 1,3-cyclohexandione
(0.22 gm), cycloheptanone (0.24), or dimidone, (0.28 gm),
was stirred in a mixture of methanol (5mL) and 5 drops of
NH4OH at room temperature for 3–5 min. After completion
of the reaction (monitored by TLC), the formed product was
filtered off, washed with small amounts of water (10mL) and
then cold methanol (5mL), dried, and crystallized from ethanol.
% inhibition of edema (% mean SE)
Compound. no
1 h
0.00
2 h
3 h
Control
Indomethacin
Celecoxib
3
4
5
6
7
0.00
0.00
31.51 2.32
31.43 2.87
31.00 1.03* 40.96 2.27*
32.79 1.48* 45 1.02*
30.86 1.57* 41.38 3.47*
26.61 2.92* 37.15 2.93*
29.18 2.19* 40.43 2.40*
40.12 2.91
45.75 3.41
60.81 3.15
63.78 3.30
57.93 2.22*
57.12 0.92*
47.41 3.10*
44.38 2.31*
58.67 1.18*
9
10
11
26.86 1.86* 35.25 1.22** 52.81 1.17*
32.79 1.48* 45.14 1.12*
31.21 1.67* 41.22 3.19*
57.12 0.92*
55.03 1.99*
Method B.
Exposed a mixture of compound 1
*Significant difference from the control value at p < 0.01.
**Significant difference from the control value at p < 0.05.
(0.002mol, 0.55g), malononitrile (0.002mol, 0.13mL),
Journal of Heterocyclic Chemistry
DOI 10.1002/jhet

A. Khodairy, A. M. Ali, M. O. Aboelez, and M. T. El-Wassimy
Vol 000
and previous ketonic reagents (0.002mol) in sodium chlo-
ride solution (0.5M, 10mL) to ultrasonic irradiation until
dissolve and continuous for the appropriate time (Table 1).
The progress of the reaction was monitored by TLC, the
formed product was filtered off, washed with small amount
of water, dried, and crystallized from ethanol.
2-(2-Amino-5-benzoyl-3-cyano-6-methyl-4H-pyran-4-yl)phe-
nyl-4-methylbenzene sulfonate (6).
Mp. 167–169°C; IR
(KBr) cmꢀ1 3391, 3272 (NH2), 2189 (C ≡ N), 1657
(C¼O), 1368, 1165 (SO2) cmꢀ1; H NMR (DMSO-d6):
1
7.91 (d, 2H, J = 8Hz, Ar―H), 7.67–7.07 (m, 11H,
Ar―H), 7.05 (s, 2H, NH2, D2O exchangeable), 4.61 (s,
1H, CH-pyran); 2.41 (s, 3H, CH3), 1.69 (s, 3H, CH3):
13C NMR: δ 193..5, 159.41, 155.14, 146.98, 140.09,
137.96, 136.21, 134.52, 133.01, 132.52, 131.15, 130.61,
127.63, 126.57, 121.25, 118.36, 104.86, 57.19, 35.92,
21.38, 18.47: Anal. Calcd. for C27H22N2O5S (486.53): C
(66.65%), H (4.56%), N (5.76%), S (6.59%) Found:
(66.72%), H (4.61%), N (5.57%), S (6.92%)
Method C.
A mixture of compound 2 (0.001mol,
0.33g), and selected ketonic reagent (0.001 mol) was
refluxed in ethanol (20 mL) in the presence of drops of
TEA for 4–7 h (TLC monitoring). The reaction mixture
was allowed to cool to room temperature and the formed
precipitate was filtered off and crystallized from ethanol.
2-(3-Acetyl-6-amino-5-cyano-2-methyl-4H-pyran-4-yl)phenyl-
4-methylbenzene sulfonate (3).
Mp. 178–180; IR (KBr)
2-(2-Amino-3-cyano-4,5,6,7-tetrahydrocyclopenta[b]pyran-4-
yl)phenyl-4-methyl benzenesulfonate (7). Mp. 182–184°C;
IR (KBr) cmꢀ1 3321, 3264 (NH2), 2201 (C≡N), 1351,
1189 (SO2) cmꢀ1; 7.79 (d, 2H, Ar―H), 7.54–7.34 (m,
5H, Ar―H), 7.07 (m, 1H, Ar―H), 6.98 (s, 2H, NH2, D2O
exchangeable), 4.16 (s, 1H, CH-pyran); 2.94–2.74 (m, 4H,
2CH2) 2.44 (s, 3H, CH3), 1.83–1.52 (m, 4H, 2CH2): 13C
NMR: δ 157.59, 146.09, 145.14, 135.46, 134.82, 133.67,
131.56, 131.68, 127.29, 123.34, 119.13, 107.28, 56.36,
38.59, 30.19, 26.03, 21.26, 18.04 Anal. Calcd. for
C22H20N2O4S (408.47) C (64.69%), H (4.94%), N
(6.86%), S (7.85%) Found: C (64.57%), H (4.79%), N
(6.65%), S (7.43%).
cmꢀ1 3348, 3224 (NH2), 2192 (C≡N), 1661 (C¼O),
1
1351, 1129 (SO2) cmꢀ1; H NMR (DMSO-d6): 7.83 (d,
2H, J=8Hz, Ar―H), 7.42 (d, 2H, J=8.0Hz, Ar―H),
7.24–7.17 (m, 4H, Ar―H), 6.79 (s, 2H, NH2, D2O ex-
changeable), 4.37 (s, 1H, CH-pyran), 2.41 (s, 3H, CH3),
2.26 (s, 3H, CH3), 2.11 (s, 3H, CH3); 13C NMR: δ 193.91,
157.03, 135.38, 135.16, 131.42, 131.08, 129.67, 129.39,
126.71, 126.09, 123.01, 117.24, 112.13, 57.17, 36.10,
28.31, 21.04, 18.12: Anal. Calcd. for C22H20N2O5S
(424.48): C (62.25%), H (4.75%), N (6.60%), S (7.55%)
Found: C (62.39%), H (4.71%), N (6.82%), S (7.43%).
Ethyl-6-amino-5-cyano-2-methyl-4-(2-tosyloxyphenyl)-4H-
pyran-3-carboxylate (4). Mp.161–163°C; IR (KBr) cmꢀ1
3375, 3257 (NH2), 2190 (C ≡ N), 1703 (C¼O), 1364,
2-(2-Amino-3-cyano-5,6,7,8-tetrahydro-4H-chromen-4-yl)phe-
nyl-4-methylbenzene sulfonate (8).
Mp.174–176°C; IR
1
1184 (SO2) cmꢀ1; H NMR (DMSO-d6): 7.93 (d, 2H,
(KBr) cmꢀ1 3342, 3246 (NH2), 2196 (C≡N), 1381–1175
1
J =8 Hz, Ar―H), 7.53 (d, 2H, J = 8.0 Hz, Ar―H), 7.26–
7.16 (m, 4H, Ar―H), 6.77 (s, 2H, NH2, D2O exchange-
able), 4.62 (s, 1H, CH-pyran); 3.97–3.92 (q, 2H, CH2),
2.45 (s, 3H, CH3), 2.29 (s, 3H, CH3), 0.99–0.95 (t, 3H,
CH3); 13C NMR: δ 165.67, 157.51, 156.97, 147.84,
146.02, 145.56, 143.67, 131.58, 130.11, 128.69, 127.18,
124.12, 121.79, 118.28, 106.31, 59.61, 56.12, 36.84,
21.61, 18.58, 14.02: Anal. Calcd. for C23H22N2O6S
(454.49): C (60.78%), H (4.88%), N (6.16%), S (7.06%)
Found: C (60.87%), H (4.69%), N (6.32%), S (7.19).
Ethyl-6-amino-5-cyano-2-phenyl-4-(2-(tosyloxy)phenyl)-4H-
pyran-3-carboxylate (5). Mp. 162–164°C; IR (KBr) cmꢀ1
3322, 3230 (NH2), 2202 (C ≡ N), 1701 (C¼O), 1354, 1155
(SO2) cmꢀ1; H NMR (DMSO-d6): 7.89 (d, 2H, Ar―H),
7.84–7.24 (m, 6H Ar―H), 7.19 (s, 2H, NH2, D2O exchange-
able), 4.36 (s, 1H, CH-pyran), 2.46 (s, 3H, CH3), 2.41–2.19
(m, 6H, 3CH2), 1.66–1.55 (m, 2H, CH2), 13C NMR: δ
158.07, 147.41, 145.26, 136.70, 135.42, 133.14, 131.24,
131.51, 127.55, 119.21, 118.91, 109.01, 51.63, 36.68,
26.36, 22.61, 22.23, 22.02, 21.09: Anal. Calcd. for
C23H22N2O4S (422.49) C (65.38%), H (5.25%), N
(6.63%), S (7.59%) Found: C (65.52%), H (5.36%), N
(6.51%), S (7.73%).
2-(2-Amino-3-cyano-5-oxo-5,6,7,8-tetrahydro-4H-chromen-4-
yl)phenyl-4-methyl benzenesulfonate (9).
Mp. 198–200°C;
IR (KBr) cmꢀ1 3347, 3215 (NH2), 2183 (C≡N), 1678
1
1
(SO2) cmꢀ1; H NMR (DMSO-d6): 7.93 (d, 2H, J = 8Hz,
(C¼O), 1360, 1155 (SO2) cmꢀ1; H NMR (DMSO-d6):
Ar―H), 7.52 (d, 2H, J= 8.0 Hz, Ar―H), 7.50–7.44 (m,
4H, Ar―H), 7.34–7.33 (t, 1H, Ar―H), 7.31–7.29 (t, 3H,
Ar―H), 7.20–7.17 (t, 1H, Ar―H), 6.90 (s, 2H, NH2,
D2O exchangeable), 4.75 (s, 1H, CH-pyran); 3.80–3.75
(q, 2H, CH2), 2.45 (s, 3H, CH3), 0.79–0.76 (t, 3H,
7.96 (d, 2H, J=8Hz, Ar―H), 7.53 (d, 2H, J=8.0Hz,
Ar―H), 7.23–7.19 (t, 3H, Ar―H), 7.03(d, 1H, Ar―H),
7.02 (s, 2H, NH2, D2O exchangeable), 4.44 (s, 1H, CH-
pyran), 2.56–2.45 (t, 2H, CH2), 2.30–2.24 (q, 2H, CH2),
1.96 (d, 2H, CH2): 13C NMR: δ 195.93, 165.16,
159.22, 148.37, 145.95, 136.05, 133.93, 131.18, 130.71,
128.42, 128.32, 126.77, 119.88, 119.62, 11.15, 57.67,
36.75, 27.05, 21.61, 20.13; Anal. Calcd. for
C23H20N2O5S (436.48); C (63.29%), H (4.62%), N
(6.42%), S (7.35%) Found: C (63.42%), H (4.56%), N
(6.48%), S (7.26%).
CH3);13CNMR:
δ 165.87, 159.12, 155.41, 146.97,
138.57, 137.27, 134.68, 132.58, 131.99, 130.96, 129.67,
128.18, 126.28, 126.51, 121.87, 119.22, 108.29, 60.17,
56.68, 35.81, 21.15, 14.26: Anal. Calcd. for C28H24N2O6S
(516.56): C (65.10%), H (4.68%), N (5.42%), S (6.21%)
Found: C (65.13), H (4.56%), N (5.51%), S (6.29%).
Journal of Heterocyclic Chemistry
DOI 10.1002/jhet

Month 2016
One-Pot Multicomponent
2-(2-Amino-3-cyano-4,5,6,7,8,9-hexahydrocyclohepta[b]pyran-
4-yl)phenyl-4-methyl benzenesulfonate (10). Mp. 193–195°C;
IR (KBr) cmꢀ1 3359, 3241 (NH2), 2206 (C≡N), 1368, 1187
2-(6-Amino-5-cyano-3-methyl-1-phenyl-1,4-dihydropyrano
[2,3-c]pyrazol-4-yl) phenyl 4-methylbenzenesulfonate (13).
Mp. 231–233°C; IR (KBr) cmꢀ1 3362, 3289 (NH2), 2203
1
1
(SO2) cmꢀ1; H NMR (DMSO-d6): 7.87 (d, 2H, Ar―H),
(C ≡ N), 1372, 1173 (SO2) cmꢀ1; H NMR (DMSO-d6):
7.56–7.34 (m, 6H, Ar―H), 7.11 (s, 2H, NH2, D2O exchange-
able), 4.19 (s, 1H, CH-pyran), 2.47 (s, 3H, CH3), 1.73 –1.59
(m, 2H, CH2), 1.31–1.28 (m, 4H, CH2), 1.09–99 (m, 4H,
CH2): 13C NMR: δ 159.15, 147.37, 146.41, 140.42, 134.60,
133.43, 131.12, 131.38, 128.85, 127.31, 122.28, 119.11,
108.35, 54.13, 36.81, 31.27, 31.55, 27.31, 27.59, 25.67,
21.12 Anal. Calcd. for C24H24N2O4S (436.52) C (66.03%),
H (5.54%) N (6.42%) S (7.35%) Found: C (66.09%), H
(5.31%), N (6.63%), S (7.27%).
7.88 (d, 2H, Ar―H), 7.67 (d, 2H, Ar―H), 7.59–7.18 (m,
7H, Ar―H), 7.09 (s, 2H, NH2, D2O exchangeable), 7.06
(d, 2H, Ar―H), 4.85 (s, 1H, CH-pyran), 2.46 (s, 3H,
CH3), 1.76 (s, 3H, CH3); 13C NMR: δ 160.98, 155.87,
147.05, 146.69, 138.21, 137.53, 137.12, 131.96, 130.76,
130.08, 129.21, 129.06, 128.57, 128.23, 126.78, 123.23,
122.25, 120.32, 97.76, 57.36, 30.18, 21.65, 10.14: Anal.
Calcd. For C27H22N4O4S (498.68) C (65.05%), H
(4.45%), N (11.24%), S (6.43%) Found C (65.21%), H
(4.62%), N (11.39%), S (6.57%).
4-(2-Amino-3-cyano-7,7-dimethyl-5-oxo-5,6,7,8-tetrahydro-4H-
chromen-4-yl)phenyl 4-methylbenzenesulfonate (11). Mp. 243–
245°C; IR (KBr) cmꢀ1 3334, 3259 (NH2), 2197
(C ≡ N), 1678 (C¼O), 1375–1163 (SO2) cmꢀ1
;
1H
CONCLUSION
NMR (DMSO-d6): 7.76–7.68 (m, 3H, Ar―H), 7.46–
7.26 (m, 3H, Ar―H), 7.18–7.01 (m, 4H, Ar―H +2H,
NH2, D2O exchangeable), 4.24 (s, 1H, CH-pyran), 2.41
(s, 3H, CH3), 2.23 (s, 2H, CH2), 2.20 (s, 2H, CH2),
1.17 (s, 3H, CH3), 0.98 (s, 3H, CH3): 13CNMR: δ
193.91, 161.02, 156.39, 147.27, 146.98, 145.13,
136.19, 133.46, 131.93, 127.06, 126.51, 124.63,
116.19, 111.09, 59.63, 51.76, 33.58, 32.42, 27.83,
26.53, 21.42: Anal. Calcd. for C25H24N2O5S (464.48) C
(64.64%), H (5.21%), N (6.03%), S (6.90%) Found: C
(64.56%), H (5.43%), N (6.06%), S (6.61%).
2-Tosyloxybenzaldehyde can be used for synthesis of 2-
tosyloxyphenylpyrans and 2-tosyloxyphenylpyranopyrazoles
via one-pot, MCR under green and conventional conditions.
In general, the products were obtained in high yield and short
reaction time using green methods. Some selected com-
pounds were screening anti-inflammatory activity and
showed good activity.
Acknowledgments. We are thankful to Sohag University, Egypt,
Sohag for the support of this work.
General
procedure
for
preparation
of
2-
tosyloxyphenylpyrano[2–3c]pyrazole derivatives 12 and 13.
A
mixture of 2-tosyloxybenzaldehyde (1) (0.002 mol,
0.55g), malononitrile (0.002mol, 0.13 mL), and appropri-
ate reagent (0.002mol), namely hydrazine hydrate
(0.10 mL) or phenyl hydrazine (0.20 mL), and ethyl
acetoacetate (0.26 mL) was refluxed in ethanol (20 mL)
containing drops of TEA for 5 h (TLC monitoring). The re-
action mixture was allowed to cool to room temperature
and the formed precipitate was filtered off and crystallized
from ethanol.
REFERENCES AND NOTES
[1] Butler, R. N.; Katritzky, A. R.; Rees, C. W.; Scriven, E. F. V.
Comprehensive Heterocyclic Chemistry; Pergamon Press: Oxford, UK,
1996, pp 4.
[2] Morgan, L. R.; Jursic, B. S.; Hooper, C. L.; Neumann, D. M.;
Thangaraj, K.; Leblance, B. Bioorg Med Chem Lett 2002, 12, 3407.
[3] Moon, D. O.; Kim, K. C.; Jin C. Y.; Han, M. H.; Park, C.; Lee,
K. J.; Park, Y. M.; Choi, Y. H.; Kim, G. Y. Int Immunopharmacol 2007,
7, 222.
[4] Wu, J. Y. C.; Fong, W. F.; Zhang, J. X.; Leung, C. H.; Kwong,
H. L.; Yang, M. S.; Li, D.; Cheung, H. Y. Eur J Pharmacol 2003, 473, 9.
[5] Flavin, M. T.; Rizzo, J. D.; Khilevich, A.; Kucherenko, A.;
Sheinkman, A. K.; Vilaychack, V.; Lin, L.; Chen, W.; Greenwood, E.
M.; Pengsuparp, T.; Pezzuto, J. M.; Hughes, S. H.; Flavin, T. M.;
Cibulski, M.; Boulanger, W. A.; Shone, R. L.; Xu, Z. Q. J Med Chem
1996, 39, 1303.
[6] Kumar, A.; Maurya, R. A.; Sharma, S. A.; Ahmad, P.; Singh,
A. B.; Bhatia, G.; Srivastava, A. K. Bioorg Med Chem Lett 2009, 19,
6447.
[7] De Andrade-Neto, V. F.; Goulart, M. O.; DaSilva Filho, J. F.;
DaSilva, M. J.; Pinto, M. D. C.; Pinto, A. V.; Zalis, M. G.; Carvalho, L.
H.; Krettli, A. U. Bioorg Med Chem Lett 2004, 14, 1145.
[8] Raj, T.; Bhatia, R. K.; Kapur, A.; Sharma, M.; Saxena, A. K.;
Ishar, M. P. S. Eur J Med Chem 2010, 45, 790.
[9] Armstrong, R. W.; Combs, A. P.; Tempest, P. A.; Brown, S.
D.; Keating, T. A. Acc Chem Res 1995, 29, 123.
[10] (a) Lu, P.; Wang, Y. G. Synlett 2010, 165; (b) Ganem, B.
Acc Chem Res 2009, 42, 463; (c) Domling, A. Chem Rev 2006,
106, 17.
2-(6-Amino-5-cyano-3-methyl-1,4-dihydropyrano[2,3-c]pyrazol-
4-yl)phenyl-4-methylbenzenesulfonate (12). Mp. 217–219°C;
IR (KBr) cmꢀ1 3369, 3219, 3203 (NH2 +NH), 2196
1
(C≡N), 1396, 1182 (SO2) cmꢀ1; H NMR (DMSO-d6):
12.10 (s, 1H, NH, D2O exchangeable), 7.85 (d, 2H, Ar―H),
7.53 (d, 2H, Ar―H), 7.28–7.09 (m, 4H, Ar―H), 6.81 (s,
2H,NH2, D2O exchangeable), 4.92 (s, 1H, CH-pyran), 2.44
(s, 3H, CH3), 1.74 (s, 3H, CH3); 13C NMR: 13C NMR:
161.65, 155.65, 147.32, 146.35, 136.92, 136.06, 132.69,
130.84, 130.51, 128.77, 128.48, 128.07, 121.50, 120.42,
96.89, 56.67, 30.62, 21.64, 9.98; DEPT 135 δ 130.84,
130.51, 120.77, 120.07, 121.51, 36.52, 21.64, 9.58 Anal.
Calcd. For C21H18N4O4S (422.52) C (59.70%), H (4.29%),
N (13.26%), S (7.59%); Found C (59.64%), H (4.42%), N
(13.19%). S (7.63%).
Journal of Heterocyclic Chemistry
DOI 10.1002/jhet

A. Khodairy, A. M. Ali, M. O. Aboelez, and M. T. El-Wassimy
Vol 000
[11] Khodairy, A.; Shaaban, K. M.; Ali, M. A.; El-Wassimy, M. T.;
Nagwa, S. J Chem Pharm Res 2015, 7, 332.
[12] Chen, H.; Shi, D. J Comb Chem 2010, 12, 571.
[13] Safari, J.; Banitaba, S. H.; Khalili, S. D. Ultrason Sonochem
2012, 19, 1061.
[21] Zhang, Z. H.; Li, J. J.; Li, T. S. Ultrason Sonochem 2012, 19, 264.
[22] Nagargoje, D.; Mandhane, P.; Shingote, S.; Badadhe, P.; Gill,
C. Ultrason Sonochem 2012, 19, 94.
[23] Dabiri, M.; Tisseh, Z. N.; Bahramnejad, M.; Bazgir, A.
Ultrason Sonochem 2011, 18, 1153.
[14] Zou, Y.; Wu, H.; Hu, Y.; Liu, H.; Zhao, X.; Ji, H. Shi Ultrason
Sonochem 2011, 18, 708.
[24] Trilleras, J.; Insuasty, B.; Abonía, R.; Nogueras, M.; Cobo, J.
Revista Ciencias 2008, 12, 123.
[15] Kandhasamy, K.; Gnanasambandam, V. Current Organic
Chemistry 2009, 13, 1820.
[25] Khodairy, A.; Ali M. A., El-Wassimy, M. T. J Heterocyclic
Chem 2015, DOI: 10.1002/jhet.2461.
[16] Andrade, C. K. Z.; Alves, L. M. Curr Top Med Chem 2005, 9,
195–218.
[26] Mourad, A. F. E.; Amer, A. A.; El-Shaieb, K. M.; Ali, A. M.;
Aly, A. A. J Heterocyclic Chem 2016, 53, 383.
[17] Li, J. T.; Zhang, X. H.; Lin, Z.-P. Beilstein J Org Chem 2007, 3, 1.
[18] Li, J. T.; Yang, W. Z.; Wang, S. X.; Li, S. H.; Li, T. S.
Ultrason Sonochem 2002, 9, 237.
[19] [19]. Zare, L.; Mahmoodi, N. O.; Yahyazadeh, A.;
Nikpassand, M. Ultrason Sonochem 2012, 19, 740.
[20] Saleh, T. S.; El-Rahman, N. M. A.; Elkateb, A. A.; Shaker, N. O.;
Mahmoud, N. A.; Gabal, S. A. Ultrason Sonochem 2012, 19, 491.
[27] Winter, C. A.; Risley, E. A.; Nuss, G. W. Exp Biol Med 1962,
111, 544.
[28] [28] Nojima, H.; Tsuneki, K. I.; Kimura, M. Br J Pharmacol
1995, 116, 1680.
[29] Shoman, M. E.; Abdel-Aziz, M.; Aly, O. M.; Farag, H. H.;
Morsy, M. A. Eur J Med Chem 2009, 44, 3068.
[30] Hano, J. J.; Bugajshi, I. D. Pol J Pharmacol 1976, 28, 37.
Journal of Heterocyclic Chemistry
DOI 10.1002/jhet